|
Today, the U.S. Food and Drug Administration (FDA) issued a Letter to Health Care Providers to notify providers that we are aware that the United States is experiencing interruptions in the supply of Stereotactic Breast Biopsy Needles because of recent supplier issues. The FDA also updated the expected shortage duration for Stereotactic Breast Biopsy Needles on the medical device shortage list (product code KNW).
The disruption in availability of this device is expected to impact patient care and may require adjustments to the clinical management of patients indicated to undergo a breast biopsy.
The FDA recommends health care providers consider strategies to conserve the use of Stereotactic Breast Biopsy Needles when possible.
The Letter to Health Care Providers includes important information about the shortage of Stereotactic Breast Biopsy Needles:
-
Recommendations for health care providers.
-
Actions that the FDA is taking to assess and mitigate the risk.
-
Instructions for reporting problems with a device.
Questions?
|
|
|
|
